EFFICACY AND TOLERABILITY OF TIP (PACLITAXEL, IFOSFAMIDE AND CISPLATIN) INCORPORATED INTO INDUCTION CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE- OR POOR-RISK METASTATIC GERM CELL TUMORS

被引：0
|
作者：
Nishikawa, Masatomo
Miyake, Hideaki
Fujisawa, Masato
机构：
来源：
JOURNAL OF UROLOGY | 2015年 / 193卷 / 04期
关键词：
D O I：
10.1016/j.juro.2015.02.415
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP10-14
引用
收藏
页码：E116 / E116
页数：1
相关论文
共 50 条
  • [1] Efficacy and tolerability of TIP (paclitaxel, ifosfamide and cisplatin) incorporated into induction chemotherapy for patients with intermediate- or poor-risk metastatic germ cell tumors
    Masatomo Nishikawa
    Hideaki Miyake
    Mototsugu Muramaki
    Masato Fujisawa
    Medical Oncology, 2014, 31
  • [2] Efficacy and tolerability of TIP (paclitaxel, ifosfamide and cisplatin) incorporated into induction chemotherapy for patients with intermediate- or poor-risk metastatic germ cell tumors
    Nishikawa, Masatomo
    Miyake, Hideaki
    Muramaki, Mototsugu
    Fujisawa, Masato
    MEDICAL ONCOLOGY, 2014, 31 (12) : 1 - 7
  • [3] Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors
    Feldman, Darren R.
    Hu, James
    Dorff, Tanya B.
    Lim, Kristina
    Patil, Sujata
    Woo, Kaitlin M.
    Carousso, Maryann
    Hughes, Amanda
    Sheinfeld, Joel
    Bains, Manjit
    Daneshmand, Siamak
    Ketchens, Charlene
    Bajorin, Dean F.
    Bosl, George J.
    Quinn, David I.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (21) : 2478 - +
  • [4] Paclitaxel, ifosfamide, and cisplatin (TIP) efficacy for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)
    Feldman, Darren Richard
    Hu, James
    Dorff, Tanya B.
    Patil, Sujata
    Van Alstine, Lindsay Joy
    Momen, Lamia
    Carousso, Maryann
    Hughes, Amanda
    Snively-Solomon, Jolie
    Ketchens, Charlean
    Sheinfeld, Joel
    Bains, Manjit S.
    Bajorin, Dean F.
    Bosl, George J.
    Motzer, Robert John
    Quinn, David I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)
    Feldman, Darren Richard
    Hu, James
    Dorff, Tanya B.
    Patil, Sujata
    Van Alstine, Lindsay Joy
    Momen, Lamia
    Carousso, Maryann
    Hughes, Amanda
    Snively-Solomon, Jolie
    Ketchens, Charlean
    Sheinfeld, Joel
    Bains, Manjit S.
    Bajorin, Dean F.
    Bosl, George J.
    Motzer, Robert John
    Quinn, David I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [6] Re: Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients with Intermediate- or Poor-Risk Germ Cell Tumors Editorial Comment
    Richie, Jerome P.
    JOURNAL OF UROLOGY, 2017, 198 (02): : 257 - 257
  • [7] Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors
    Pectasides, Dimitrios
    Pectasides, Eirini
    Papaxoinis, George
    Xiros, Nikolaos
    Kamposioras, Konstantinos
    Tountas, Nikolaos
    Economopoulos, Theofanis
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (06) : 617 - 623
  • [8] Testicular Function in Poor-Risk Nonseminomatous Germ Cell Tumors Treated With Methotrexate, Paclitaxel, Ifosfamide, and Cisplatin Combination Chemotherapy
    Pectasides, D.
    Pectasides, E.
    Papaxoinis, G.
    Skondra, M.
    Gerostathou, M.
    Karageorgopoulou, S.
    Kamposioras, C.
    Tountas, N.
    Koumarianou, A.
    Psyrri, A.
    Macheras, A.
    Economopoulos, T.
    JOURNAL OF ANDROLOGY, 2009, 30 (03): : 280 - 286
  • [9] Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).
    Feldman, Darren R.
    Hu, James S.
    Patil, Sujata
    Reuter, Victor E.
    Srinivas, Sandy
    Stadler, Walter Michael
    Costello, Brian Addis
    Milowsky, Matthew I.
    Appleman, Leonard Joseph
    Dorff, Tanya B.
    Bromberg, Maria
    Joseph, Gabriella
    Funt, Samuel Aaron
    Bajorin, Dean F.
    Bosl, George J.
    Quinn, David I.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] The Changing Landscape of Intermediate- and Poor-Risk Germ Cell Tumors: Do We Need to Reclassify Patients With Metastatic Germ Cell Tumors?
    Necchi, Andrea
    Nicolai, Nicola
    Giannatempo, Patrizia
    Raggi, Daniele
    Miceli, Rosalba
    Mariani, Luigi
    Salvioni, Roberto
    CLINICAL GENITOURINARY CANCER, 2016, 14 (01) : 1 - 4
12345